COSCIENS Biopharma Inc.
CSCIF
$4.98
-$0.32-6.04%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -7.97% | -15.29% | -26.43% | -4.67% | 25.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.97% | -15.29% | -26.43% | -4.67% | 25.60% |
| Cost of Revenue | -5.61% | 2.77% | -1.67% | -35.81% | -27.54% |
| Gross Profit | -10.76% | -35.62% | -51.87% | 163.92% | 831.83% |
| SG&A Expenses | 9.95% | 11.32% | 45.27% | -22.39% | 8.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.06% | -25.67% | -17.69% | 18.58% | 73.83% |
| Operating Income | 46.34% | 34.26% | 9.24% | -79.97% | -183.99% |
| Income Before Tax | 73.41% | 59.92% | 41.29% | -309.84% | -1,159.53% |
| Income Tax Expenses | -98.97% | -97.58% | -85.71% | 157.57% | 154.88% |
| Earnings from Continuing Operations | 74.84% | 61.05% | 41.54% | -1,077.84% | -3,857.33% |
| Earnings from Discontinued Operations | 876.99% | 1,171.66% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 134.78% | 123.08% | 32.34% | -1,200.70% | -4,160.78% |
| EBIT | 46.34% | 34.26% | 9.24% | -79.97% | -183.99% |
| EBITDA | 24.21% | 13.67% | -17.52% | -343.15% | -484.79% |
| EPS Basic | 134.95% | 122.60% | 39.26% | -273.39% | -112.53% |
| Normalized Basic EPS | 49.87% | 28.33% | 3.93% | -11.20% | 25.83% |
| EPS Diluted | 134.92% | 122.57% | 39.26% | -272.90% | -112.41% |
| Normalized Diluted EPS | 49.87% | 28.33% | 3.93% | -11.20% | 25.83% |
| Average Basic Shares Outstanding | 0.76% | 9.00% | 22.74% | 15.53% | 38.96% |
| Average Diluted Shares Outstanding | 0.76% | 9.00% | 22.74% | 15.53% | 38.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |